GLP-1s and the Heart: What the Outcome Trials Showed

The heart headlines about GLP-1s are everywhere, and they run on a shorthand that hides more than it reveals: good for the heart. Which medicine, for whom, proven how, and what the proof actually consists of, are the questions the shorthand skips. The answers all live in public documents, in the indications section of the prescribing information, each one traceable to a specific trial that a regulator reviewed.

This article reads those documents plainly. It covers what a cardiovascular outcome trial is and why regulators require them, what each product's label now says, the trial that extended this class from diabetes care into weight management, and how to read a percentage reduction without turning it into a personal forecast. One warning up front: every number here is a group result in a studied population. None of it predicts what any medicine will do for you.

What an outcome trial is, and why regulators want them

Most clinical trials measure proxies: a blood sugar number, a weight on a scale, a lab value that moves within months. A cardiovascular outcome trial measures events instead. It follows thousands of people for years and counts a defined combination of serious outcomes, and it asks whether the medicine changed how often they happened.

Regulators require these trials for a blunt reason: a medicine can improve every proxy on the chart while leaving the outcomes that actually matter unchanged, and only a long trial counting real events can tell the difference. The outcome the labels use is major adverse cardiovascular events, and the labels define it: cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. When a label says a medicine is indicated to reduce the risk of that combination, it means a trial counted those events, in a defined population, over years, and a regulator reviewed the count.

That is the machinery behind every heart headline about these medicines. With it in place, the labels themselves can be read product by product, which is the next section.

What each label says

Three products in this class carry cardiovascular indications, and the wording of each matters.

• Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
• Ozempic is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• Trulicity is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Read the populations as closely as the outcomes. Each indication names who was studied, and the names differ: Wegovy's population has established cardiovascular disease with obesity or overweight and is not defined by diabetes; Ozempic's has type 2 diabetes with established cardiovascular disease; Trulicity's includes people with multiple risk factors rather than established disease. This article deliberately does not rank the products against each other, because an indication is not a ranking. It is a record of what was studied and approved.

Why Zepbound's silence is not a verdict

Zepbound's indications are reducing excess body weight and maintaining that reduction, and treating moderate to severe obstructive sleep apnea in adults with obesity. It carries no cardiovascular outcome indication.

That absence needs explaining carefully, because it is the most misread fact in this subject. An indication reflects the trials a company ran and the FDA reviewed. Its absence means that use has not been approved on that evidence. It is not evidence that the medicine fails to help the heart. Absence of an indication is a statement about paperwork completed, not about biology.

Tirzepatide itself has since supplied the proof. Mounjaro, the same molecule under a different brand name, now carries an indication to reduce the risk of major adverse cardiovascular events, cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in adults with type 2 diabetes who are at high risk for them. Zepbound still carries none. One molecule, two labels, two different answers to the same question, settled by which trials were run under which brand name. The two labels sit side by side in Mounjaro vs Zepbound: Same Molecule, Different Labels.

This is also why comparing products on the basis of their indication lists misleads. The honest comparison of semaglutide and tirzepatide as medicines, their dosing, their studied effects, is its own subject in Semaglutide vs Tirzepatide: The Differences That Matter for Tracking; the indication lists are not a shortcut to that comparison.

SELECT: the trial that crossed into weight management

Of all the outcome trials behind those labels, one changed the conversation most, because it moved the heart question out of diabetes care and into weight management. The Wegovy indication came from the SELECT trial, published in the New England Journal of Medicine in December 2023.

SELECT enrolled people with established cardiovascular disease and overweight or obesity, and specifically without diabetes. That exclusion is the whole point: it meant the trial could ask whether the medicine reduced cardiovascular risk in people whose connection to it was weight, not blood sugar. Over a mean of about 40 months, semaglutide 2.4 mg reduced the three-part outcome of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 20 percent. The FDA approved the cardiovascular indication in March 2024.

From that trial came a sentence in a label, and on the strength of that sentence thousands of people now take a medicine whose original home was diabetes care. It is worth pausing on how much distance sits between the trial and the headline: years of follow-up, a defined population, a counted outcome, a regulator's review. Every one of those steps is what makes the label sentence trustworthy, and every one of them is what the shorthand drops.

GLP 1 Tracker AppKeep the GLP-1 part of your plan straight: every dose dated, with notes, alongside the rest of your treatment. Get the app

How to read a 20 percent reduction honestly

So what does 20 percent mean, and what does it not mean? It is a relative reduction in a counted outcome across a trial population followed for a mean of about 40 months. Fewer of the bad events counted in the group that received the medicine than in the group that did not, by that proportion.

What it is not is a forecast. It is not a 20 percent reduction in your personal risk, because no trial measured you. Group averages over years in a studied population do not transfer to individuals, and the transfer is exactly where honest writing stops and marketing begins. The same discipline applies to the kidney indication discussed in GLP-1s and Your Kidneys: Why Dehydration Is the Risk: a group result, carefully scoped, is a real finding and a real basis for a prescriber's decision, and it is still not a promise to any one person.

There is a further honesty note that belongs here. The population in SELECT had established cardiovascular disease, which means the events being counted were ones that population was genuinely at risk of. Whether and how any of this applies to someone with a different history is precisely the judgment a cardiologist or prescriber makes, with the full chart in view. The article you are reading supplies the reading material for that conversation, not the conclusion of it.

Your part of the plan

A cardiovascular indication changes nothing about the practical reality of treatment: these medicines arrive as one part of a plan. Around them sit the other prescriptions, the appointments, the lifestyle work, the monitoring, each piece maintained by a different part of the system and most of them invisible to each other.

Your part of that plan is the part you can hold: taking the medicine as prescribed, on the schedule prescribed, and keeping a record that shows it happened. A dated dose log does that, and a note attaches to every entry when something worth remembering happened around a shot. Getting the most out of the appointments that surround the plan, including what to bring and what clinicians tend to ask for, is its own skill, covered in Make Your Next Appointment Count: Bringing Data to the Doctor.

That is where this subject lands for a reader. The trials are real, the labels record them, the percentages describe groups over years, the absences are not verdicts, and the heart questions that matter are yours, for the clinician who knows your history. What an article can add is clarity about what the documents say, and what a log can add is the record of your part of the plan. Both are worth keeping straight.